-+ 0.00%
-+ 0.00%
-+ 0.00%

LeonaBio presents ATH-1105 ALS program at annual ALS Drug Development Summit

PUBT·06/04/2026 11:02:56
Listen to the news
LeonaBio presents ATH-1105 ALS program at annual ALS Drug Development Summit
  • LeonaBio presented at the 5th Annual ALS Drug Development Summit in Boston, held June 2-4, 2026.
  • It outlined Phase 1 support for ATH-1105, set a Phase 2 ALS trial start in 2H 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LeonaBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606040700PRIMZONEFULLFEED9731816) on June 04, 2026, and is solely responsible for the information contained therein.